SME Instrument funding awarded for Finnish technology company Biomendex Oy← Back to press releases
Biomendex Oy has
developed a revolutionary synthetic bone graft substitute for bone
regeneration. The invention, Adaptos™ is the first bioactive bone graft
substitute that surgeons can cut, shape or squeeze into place, while
eliminating bone harvesting in patients. Biomendex is changing the way bone
voids are treated, by providing the bone graft substitutes that lead to better
surgical outcomes, reduced operation time and risks, as well as lead to
SME Instrument provides an excellent opportunity for small and medium sized
companies to get financial support for product development and commercial
Applying for Horizon 2020 SME Instrument should be considered if your company:
- has developed a novel technological solution with a superior value proposition
- has already contracted the first customers and believes there is strong market demand for the solution
- has tested and validated a prototype proving the benefits of the technology.
The next SME Instrument cut-off date for Phase 2 projects is 09.10.2019. Invent Baltics OÜ provides initial consultancy regarding funding opportunities within the Horizon 2020 Research and Innovation programme free of charge.